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Abstract
Background—Surgical N95 filtering facepiece respirators (FFRs), certified by the National 
Institute for Occupational Safety and Health (NIOSH) as a respirator and cleared by the Food and 
Drug Administration (FDA) as a surgical mask, are often used to protect from the inhalation of 
infectious aerosols and from splashes/sprays of body fluids in health care facilities. A shortage of 
respirators can be expected during a pandemic. The availability of surgical N95 FFRs can 
potentially be increased by incorporating FDA clearance requirements in the NIOSH respirator 
approval process.
Methods—Fluid resistance of NIOSH-approved N95 FFRs, and FDA-cleared surgical N95 FFRs 
and surgical masks was tested using the ASTM F1862 method at 450 and 635 cm/sec velocities 
and compared with the results from a third-party independent laboratory. Blood penetration 
through different layers of filter media of masks were also analyzed visually.
Results—Four N95 FFR models showed no test failures at both velocities. The penetration 
results obtained in the NIOSH laboratory were comparable to those from the third-party 
independent laboratory. The number of respirator samples failing the test increased with 
increasing test velocity.
Conclusions—The results indicate that several NIOSH-approved N95 FFR models would likely 
pass FD clearance requirements for resistance to synthetic blood penetration.
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Surgical mask (SM) or facemask refers to the Food and Drug Administration (FDA)-cleared 
surgical, laser, isolation, dental, and medical procedure masks with or without a face shield. 
A SM covers the user’s nose and mouth and provides a physical barrier to splashes/sprays of 
large droplets of body fluids.1 SMs are used by health care personnel during surgical and 
nonsurgical procedures to protect both the patient and the health care worker from splashes/
sprays of blood or other body fluids.2 FDA clears SMs based on manufacturer-submitted test 
data and proposed claims.3 Manufacturers submit the test results for particle filtration 
efficiency, bacterial filtration efficiency, fluid resistance, differential pressure, and 
flammability for FDA clearance.3
The use of respirators certified by the National Institute for Occupational Safety and Health 
(NIOSH), at least as protective as a N95 filtering facepiece respirator (N95 FFR), is 
recommended during care of patients with diseases such as tuberculosis and measles and 
during aerosol-generating procedures on patients with certain infectious diseases (eg, 
seasonal influenza, novel influenza A, and Ebola virus disease).4–7 NIOSH tests and 
certifies the performance of FFRs according to requirements outlined in the US Title 42 
Code of Federal Regulations (CFR) Part 84.8 For N95 FFRs, the primary tests are filtration 
efficiency and airflow resistance.
The need for N95 FFRs with SM capabilities (eg, fluid resistance and flammability) was 
initially addressed, starting in 1996, by the FDA with the introduction of surgical N95 
respirators. These are NIOSH-approved N95 FFRs that have been cleared by the FDA for 
fluid resistance and flammability. The surgical N95 FFRs offer the protection of both an 
N95 FFR and a SM. Because of these properties, surgical N95 FFRs are preferably used by 
health care personnel when protection from either fluids or aerosols, or both, may be needed. 
Currently, FDA clears only a small percentage of the total number of NIOSH-certified N95 
FFR models under the Surgical N95 Respirators category. The use of surgical N95 FFRs in 
surgical and nonsurgical environments increases during outbreaks involving a known or 
suspected respiratory pathogen. For example, a scarcity of respirators during the spread of 
severe acute respiratory syndrome9 and influenza10 has been reported.
One possible option to increase the availability of surgical N95 FFRs for protection against 
inhalational hazards would be to expand NIOSH certification of N95 FFR models to include 
additional protection for fluid resistance and flammability. To better assess this option, 
NIOSH published a request for information in the Federal Register (Docket 
CDC-2014-0005) on the desirability of incorporating additional requirements and tests in the 
42 CFR Part 84 respirator approval process to match the FDA clearance requirements for 
surgical N95 respirators.11 NIOSH provided data in the docket showing that non-FDA 
cleared, NIOSH-approved respirators were routinely used in health care and that several 
models of these types of devices were included in the United States Strategic National 
Stockpile for use during public health emergencies such as a pandemic. NIOSH solicited 
data on the performance of non-FDA cleared, NIOSH-approved respirators for fluid 
resistance against splashes/sprays faced by health care workers. Comments to the docket11 
did not include data on the fluid resistance properties of non-FDA cleared N95 FFRs.
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Manufacturers evaluate fluid resistance of SMs and surgical N95 FFRs according to the 
ASTM F1862 method.12 This method is also being used to test the fluid resistance of 
respirators for research purposes.13 The fluid resistance test is a qualitative method based on 
visual inspection. Resistance to synthetic blood penetration is tested at 3 different velocities; 
450, 550, and 635 cm/sec, corresponding to the range of human blood pressures 80, 120, and 
160 mm Hg, respectively. FDA clearance3 of a surgical N95 FFR requires testing of 32 
samples for each model. Of the 32 samples, >29 (>90.6%) must pass the ASTM F1862 fluid 
resistance test at any of the above 3 velocities. FDA clears surgical N95 FFRs at 3 levels of 
fluid resistance based on their performance at 3 different velocities. Fluid resistance at low, 
medium, and high levels refers to the device passing the test at 450, 550, and 635 cm/sec 
velocities, respectively. The level of fluid resistance is directly related to the test velocity.14 
Some models may pass the testing only at 450 cm/sec, whereas others may also pass at 550 
cm/sec or even at 635 cm/sec. The model that passes the test at the highest velocity would 
have higher level of resistance compared with other models that pass the test only at the 
lower velocities (450 and 550 cm/sec).
In this study, NIOSH-approved N95 FFRs commonly used in industrial workplaces were 
evaluated for fluid resistance. N95 FFRs from 6 manufacturers were tested for resistance to 
synthetic blood penetration using the ASTM F1862 standard method at NIOSH 
(Morgantown, WV) and the results were compared with those obtained from a third-party 
independent (TPI) laboratory (Nelson Laboratory, Salt Lake City, Utah). In parallel, 
resistance testing was done for 3 FDA-cleared surgical N95 FFR and 2 SM category 
devices. The pass/fail results of N95 FFRs, surgical N95 FFRs, and SMs at 450 and 635 
cm/sec velocities were evaluated. The consistency of the test method was assessed by 
comparing the results obtained from NIOSH laboratory with the results from the TPI 
laboratory. The results, limitations of the test method, and future needs are discussed.
MATERIALS AND METHODS
Test materials
Six N95 FFR models, 3 surgical N95 FFR models, and 2 SM models were selected for this 
study. Two surgical N95 models were chosen for their identical physical appearance with 2 
non-FDA cleared N95 models, whereas others were selected randomly from leading 
manufacturers (based upon market share) and from those in the Strategic National Stockpile. 
The manufacturers and devices are: N95 FFRs: 3M (model 8210; St. Paul, MN), 3M (model 
9210), Drager (model 1350; Pittsburgh, PA), Moldex (model 2200; Culver City, CA), 
Kimberly-Clark (model 62,126; Dallas TX), and Sperian-Willson (model SAF-T-FIT; 
Franklin, PA); surgical N95 FFRs: 3M (model 1860), 3M (model 1870), and Kimberly-
Clark (model 46,727); SMs: 3M (model 1820) and Precept (model 15,320; Arden, NC). The 
N95 FFRs were labeled randomly as A, B, C, D, E, and F, the surgical N95 FFRs as G, H, 
and I, and the SMs as J and K. None of the N95 FFRs and surgical N95 FFRs had an 
exhalation valve.
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A synthetic blood penetration test apparatus (Blood Spurt Tester, model SDL, Atlas LLC, 
Rock Hill, SC), similar to the 1 described in the ASTM standard,12 was used in our study. 
The test apparatus consists of a specimen-holding fixture, a targeting plate, a pressurized 
fluid reservoir, a pneumatically actuated valve with an interchangeable canula (18-gauge 
stainless steel with an internal diameter of 0.084 cm), and a valve controller. The canula size 
was suitable to test synthetic blood penetration at arterial blood pressures ranging from 80–
120 mm Hg corresponding to 450–635 cm/sec velocities. The specimen holder and the 
supporting frame of the fixture were rigid to resist the impact of the blood-spraying process. 
The height of the specimen holder was 420 mm, corresponding to the height of the synthetic 
blood reservoir. A targeting plate with a 0.5-cm hole was placed 1 cm in front of the mask to 
ensure that the synthetic blood hit the target area of the mask. The actuated valve was 
attached to a stable metal stand to withstand any flex during activation by the pneumatic 
control. The valve was positioned according to the ASTM F1862 method so that the exit of 
the canula was 30.5 cm from the point of impact on the specimen mask.
Preparation of test apparatus and calibration
The fluid reservoir was filled with approximately 1 L fresh synthetic blood (Johnson, Moen 
& Co Inc, Rochester, Minn) and a canula was installed on the front of the pneumatically 
controlled valve. The canula used in the method is a 1.27-cm (0.5-in) long 18-gauge 
stainless needle with an internal diameter of 0.084 cm (0.033 in). The synthetic blood 
penetration test was performed only at velocities of 450 and 635 cm/sec, corresponding to 
blood pressures of 80 and 160 mm Hg, respectively. The reservoir pressure was adjusted to 
approximately 8 psi or 12 psi to achieve a velocity of 450 cm/sec or 635 cm/sec, 
respectively. The test apparatus was calibrated for each target velocity by delivering the 
synthetic blood for a 1-second difference in spurt duration. The weight of synthetic blood 
delivered for a 0.5 second and a 1.5 second spurt were collected in separate small beakers. 
The 2 weights of the samples were recorded and the difference between the 2 weights was 
calculated. According to ASTM F1862, the target difference in weight plus lower and upper 
limits for a velocity range should be within 2% of the target. The target difference in weights 
for the test at the target velocities of 450 and 635 cm/sec were 2.506 g and 3.537 g, 
respectively. In this study, the acceptable weight range was between 2.456 g and 2.556 g for 
the 450 cm/sec velocity and was between 3.466 g and 3.607 g for the 635 cm/sec velocity, 
which were within the specified ranges.
During testing, 2.0 mL (2.0 g) synthetic blood was directed to the test sample for durations 
of 0.825 seconds and 0.550 seconds corresponding to target velocities of 450 cm/sec and 
635 cm/sec, respectively. After every 15 samples, a check was performed to ensure that the 
test apparatus was still delivering 2.0 g synthetic blood by collecting and weighing the 
output passing through the targeting hole. When the blood sample delivered showed a shift 
of >0.10 g, all prior data since the last calibration were discarded. The canula was also 
cleaned after testing 15 samples.
Before use, test samples were conditioned in an environmental chamber (Caron 
Environmental Chamber, model 6001-1, Marietta, Ohio) for 4–6 hours at a temperature of 
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21°C ± 5°C and 85% ± 5% relative humidity, to simulate the temperature and humidity 
conditions of the mask on a wearer. Each test sample was removed from the environmental 
chamber and was mounted on the testing apparatus, centered, and 2-mL synthetic blood was 
dispersed at the target velocity within a minute. The synthetic blood penetration through the 
sample was assessed visually. A control mask for each model for all category devices was 
used for comparison. A drop of the blood was placed on the inner side of the control mask 
and compared with the color on the inner side of the test sample.
DATA ANALYSIS
The fluid resistance pass/fail data for each test velocity at the NIOSH laboratory and TPI 
laboratory were combined for statistical analysis. The data at the 2 different test velocities 
and the 2 laboratories were compared by Wilcoxon signed-rank test matched pairs using 
SPSS software (version 20, IBM-SPSS Inc, Armonk, NY).
RESULTS AND DISCUSSION
Table 1 shows only NIOSH test results for synthetic blood penetration for N95 FFRs, 
surgical N95 FFRs, and SMs. All samples of four N95 FFR models showed no synthetic 
blood penetration at both 450 and 635 cm/sec test velocities. One of the other 2 N95 FFR 
models (ie, A) had penetration for one of 14 samples at 450 cm/sec and 4 of 15 samples at 
635 cm/sec. Unexpectedly, model D showed blood penetration for 5 of 15 samples at 450 
cm/sec and only 1 of 15 samples at 635 cm/sec. The reason for the higher number of 
penetrations at the lower velocity is not clear. In the case of the surgical N95 FFR category, 
all samples from 2 models (ie, H and I) passed the test at both velocities. All samples of 
model G passed the test at 450 cm/sec, but showed penetration for 2 samples at the higher 
velocity. Of the 2 SM models tested in the study, model J showed penetration for 1 of 15 
samples at both 450 and 635 cm/sec. The other model (ie, K) showed penetration for 3 of 10 
samples at 635 cm/sec, but none at 450 cm/sec.
The synthetic blood penetration results obtained at the NIOSH laboratory were compared 
with the results obtained by the TPI laboratory (Table 2). The number of samples tested at 
each velocity at the NIOSH laboratory varied from 10–15 for each model, whereas, only 10 
samples per model were tested at TPI laboratory. Despite the difference in the number of 
samples tested at the 2 laboratories, the penetration results obtained at NIOSH were 
comparable to those from the TPI laboratory. For example, the same 4 N95 FFR models (ie, 
B, C, E, and F) that showed no penetration at the NIOSH laboratory also had no penetration 
at TPI laboratory. Model A showed penetration for some samples at the 2 test velocities in 
both laboratories. Similarly, some samples of model D showed penetration at 635 cm/sec at 
both testing laboratories. No penetration was obtained for 1 surgical N95 FFR model (ie, H) 
at both 450 and 635 cm/sec in both testing laboratories. In the case of SMs, 1 model showed 
penetration at both velocities at the NIOSH laboratory, but, no penetration at TPI laboratory. 
The other model had penetration only at 635 cm/sec at the NIOSH laboratory, but at both 
velocities at the TPI laboratory. Overall, 11 of 22 test results were the same between the 2 
laboratories. Although the NIOSH laboratory found more samples (ie, 7) with higher failure 
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rates than the TPI laboratory (ie, 4), the difference was not statistically significant (P = .
327).
For FDA clearance, synthetic blood penetration for 32 samples of each device is evaluated 
using the ASTM F1862 standard test method to achieve an acceptable quality limit of 4% as 
defined in the American National Standards Institute/American Society of Quality Control15 
standard. An acceptable quality limit of 4% includes minor deviations from the standard, 
such as the acceptance of synthetic blood penetration for <3 samples (<9.4%). To pass the 
test, <3 samples can show penetration at 450 cm/sec (the lowest of the 3 test velocities) at a 
minimum. A device that passes the test only at 450 cm/sec indicates its lower fluid 
resistance level. A very high fluid resistant device passes the penetration test at all 3 
velocities.
Table 3 shows the blood penetration results for the total number of samples for all models 
tested in the study. The results for the NIOSH and TPI laboratory samples were combined, 
because only a limited number of samples were tested at each laboratory. Moreover, a 
similar trend in penetration was obtained between the 2 laboratories. Samples from 4 out of 
6 models of NIOSH-approved N95 FFRs showed no penetration. Of the other 2 N95 FFR 
models, model A had penetration for 2 of 24 samples at 450 cm/sec and 7 of 25 samples at 
635 cm/sec, indicating that model A may pass the resistance test at 450 cm/sec, but not at 
635 cm/sec. Model D showed penetration for several samples at the lower velocity at 1 of 
the laboratories (see Table 2), but not at the other. Because of the contradictory results 
obtained at the lowest velocity, whether model D will meet the fluid resistance requirement 
is uncertain. Three surgical N95 FFR models were tested in the study, of which only model 
H had no failures at either velocity. All samples of model G passed the test at 450 cm/sec, 
whereas model I had 1 sample that failed the test at 450 cm/sec. Two SM models were 
tested and only 1 of 20 samples of both models failed at the lowest velocity. For this initial 
study, we did not test the full recommended sample size of 32, so it is not possible to say 
with 100% certainty whether the N95 FFR models with <3 failures would meet the FDA 
clearance requirements or not. However, because four of the models had no failures even at 
the highest velocity for the first 20–25 samples, it would seem likely that they would pass if 
testing had continued to the recommended sample size.
Surgical N95 FFR models H and I were specifically included in this study because they 
appear to be identical to 2 non-FDA cleared N95 FFRs models (ie, C and E). Models C and I 
are both flat-folding respirators from the same manufacturer and visually appear to be 
identical except for color (1 is orange and the other is white). Similarly, E and H are 
identical in appearance, except for the labeling and packaging. As shown in Table 3, both 
pairs exhibited similar fluid resistance properties.
Overall, the results showed an increase in synthetic blood penetration with increasing test 
velocity (Fig 1), similar to other studies.16 For comparison between the 2 velocities, the 
pass/fail data obtained in the 2 test laboratories were combined.
The number of samples of the 3 categories of masks that showed penetration increased with 
increasing velocity from 450–635 cm/sec. N95 FFR, surgical N95, and SM masks showed 
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penetration for 7, 1, and 2 samples at 450 cm/sec, which increased to 16, 4, and 8 samples at 
635 cm/sec. The percentage of samples that showed penetration was significantly (P = .043) 
higher at 635 cm/sec than at 450 cm/sec. Penetration for large numbers of samples at higher 
velocity can be expected because an increase in the test velocity is likely to increase the 
permeability of the masks for fluids, including synthetic blood. Other factors include the 
configuration of the different types of filter media used in the multilayer construction of the 
mask. In general, the hydrophobic filter media-containing models are less likely to show 
penetration because of their ability to retard the penetration of a hydrophilic challenging test 
agent. The presence of a hydrophobic filter media on the outer surface may provide a barrier 
to the entry of hydrophilic water-based synthetic blood.17 The lack of penetration of the 
devices may be maintained when the outer surface is hydrophobic and dry. Penetration can 
be expected when the outer layer is wet.
To gain more information on synthetic blood resistance of the mask, penetration through the 
different layers of the masks were analyzed visually. All of the models block the initial 
spray, but differences were found in how the synthetic blood moved through the layers of 
the device. Figure 2 shows the blood penetration through different layers of respirator 
models. A representative N95 FFR sample of model C, 1 of the 4 N95 models that passed 
the resistance testing, was analyzed for blood penetration through the different layers. Blood 
color was seen on the outer and inner sides of the outer layer (model C, 1a and 1b, 
respectively) and middle layer (model C, 2c and 2d, respectively). There was no red color on 
the outer or inner side (model C, 3e and 3f, respectively) of the innermost layer of the mask 
demonstrating no blood penetration. Two N95 FFR models (A and D) failed the test as 
shown by the blood color on the inner side of the masks. Model A had 3 layers of filter 
media. The outer and inner side (model A, 1a and 1b) of the outermost layer showed a wide 
area of the synthetic blood color. The middle layer had a relatively smaller area with color 
on the outer surface (model A, 2c), which diminished on the inner side (model A, 2d), 
indicating very little blood penetration. Surprisingly, a larger area of blood color was seen 
on the outer surface of the innermost layer (model A, 3e and 3f), which increased along the 
crease line on the inner side (model A, 3f) exposed to the face. The result was consistent 
between the different samples of the same model. The results are supported by the design of 
the respirator with different layers of filter media. The outer layer was thin and hydrophobic 
and blood was able to penetrate at the velocities tested in the study. The dense middle 
hydrophobic layer can be separated into 2 layers, but is considered as a single layer for 
simplicity. Although the hydrophobic middle layer appears to decrease blood penetration 
dramatically as shown by the reduction in the area of blood color, it actually allowed the 
blood to pass through it. This can be seen by the appearance of a wide area of blood color on 
the innermost hydrophilic layer, because of its affinity toward the water-based synthetic 
blood. In the case of model D, there was an outer shell and 2 hydrophobic layers with a 
second shell layer in between (Fig 2, bottom panel). The 2 hydrophobic layers were not 
sufficient to prevent blood penetration at the test velocities. The results indicate that the 
numbers of hydrophilic and hydrophobic filter media, packing density of the layers, and the 
arrangement of the layers on the outer or inner side of the mask may influence blood 
penetration.
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The penetration of synthetic blood through hydrophobic filter media layers raises a question 
on the interpretation of the test method. In the case of model A, the inner side of the middle 
hydrophobic layer showed only traces of blood color. However, blood penetration through 
the middle layer could be seen by the wide area of color on the outer and inner sides of the 
innermost hydrophilic layer. This indicates that the innermost layer should be made of a 
hydrophilic material to reveal penetration of synthetic blood. In the absence of a hydrophilic 
layer, the device may still allow blood penetration, but it may not be easily identified by the 
test method. The results indicate the need for the development of a more accurate test 
method that can identify blood penetration on the inner side of the mask with either a 
hydrophilic or hydrophobic layer.
The synthetic blood penetration test addresses the potential for infectious biologic fluids 
reaching/touching the human face in a surgical environment. There are scenarios in which 
splashes/sprays occur outside of surgical procedures. For example, significant volumes of 
respiratory secretions from infected individuals are released at high velocity in the form of a 
sneeze or cough, which can spray or splash on a nearby individual wearing an SM or FFR. 
The possibility that some devices may allow the penetration of biologic fluids exists because 
of the wide variation in their construction. The design of many surgical N95 FFRs and N95 
FFRs prevents the inner surface of the respirators from touching a user’s face. On the other 
hand, some models with a flat-fold type respirator may touch the facial skin during 
breathing, indicating that nasal secretions can diffuse through the mask under high humidity 
conditions of the mask. One study tested human subjects wearing SMs to evaluate the 
physiologic, thermal, and subjective influence of an SM on the wearer.18 Those authors18 
reported that 11% of subjects complained about the SM sticking to the face during 
inhalation. Further studies are needed to understand the diffusion of biologic fluids through 
filter media in SMs, surgical N95 respirators, and FFRs.
The results for synthetic blood penetration tests obtained in our study may have implications 
for respirator use in the health care environment. FDA clears only a small percentage of 
NIOSH-approved N95 FFRs as surgical N95 respirators. The extensive use of surgical N95 
FFRs in surgical and nonsurgical health care practices results in shortages during 
emergencies and pandemic events involving a respiratory pathogen. To address this issue, 
NIOSH could incorporate additional test requirements in 42 CFR Part 84 respirator approval 
process to parallel the protections in the FDA clearance of surgical N95 respirators. Current 
FDA clearance procedures3 accept NIOSH respirator certification in lieu of filter efficiency 
performance and differential pressure. In theory, similar arrangements for streamlined 
approvals could be made if NIOSH began evaluating fluid resistance as part of its 
certification process. Our study showed 4 out of 6 N95 FFR models approved by NIOSH but 
not cleared by FDA likely also meet the fluid resistance requirement for surgical N95 FFR 
clearance. Even the 2 N95 FFR models that demonstrated lesser fluid resistance ability still 
had pass rates of 80% and 92% at the lowest velocity, insufficient to meet requirements of 
the standard, but suggestive of ability to provide some level of fluid resistance. A detailed 
analysis of the pros and cons of NIOSH incorporating fluid resistance requirements into 42 
CFR Part 84 respirator approval and its influence on infection control policies and respirator 
shortages is outside of the scope of this article, but is needed.
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The ability of all of the N95 FFRs tested to pass 80% or greater at the lowest velocity also 
presents an opportunity to scrutinize the need for this specific test in determining suitability 
of respirators for use in medical environments. For situations with increased respirator use 
like a pandemic, the need for protection against projectile blood at 435 cm/sec may be less 
common than the need for protection against lower-velocity splashes/sprays from coughing, 
sneezing, and talking. Additional studies are needed to determine whether non-FDA cleared 
N95 FFRs would be sufficient for these types of situations, but the preliminary data here are 
promising.
Limitations of this study include that only 6 non-FDA cleared NIOSH-approved N95 FFR 
models were tested for synthetic blood penetration. Additional models need to be tested to 
provide conclusive information on whether most N95 FFR models would meet existing 
FDA requirements for penetration resistance of synthetic blood. The ASTM F1862 standard 
test method requires 32 samples per model to obtain an acceptable quality limit of 4%. This 
means that 29 or more samples should pass the test. In our study, only 10–15 samples per 
model in each laboratory were tested for synthetic blood penetration. Future studies should 
use the 32 samples per model described in the ASTM F1862 standard test method. Other 
limitations include the subjective nature of the blood penetration test as well as the variation 
in the test results obtained by different test performers in the same laboratory as well as 
between laboratories.
Nevertheless, the synthetic blood penetration results obtained in the study indicate that many 
NIOSH-approved N95 FFRs may meet the FDA clearance requirement for synthetic blood 
penetration. Although many models would likely pass the synthetic blood penetration 
criterion, whether they would pass the flammability tests for FDA clearance remains to be 
evaluated. Studies on the blood penetration for longer times may provide information on any 
change in the penetration pattern, when the exposed mask is worn for a protracted period.
CONCLUSIONS
Four out of 6 NIOSH-approved N95 FFR models that were not cleared by FDA that were 
tested in our study showed resistance to synthetic blood penetration at 450 and 635 cm/sec 
velocities. Similar results were obtained from a TPI laboratory. The combined results for 
resistance to blood penetration from the 2 laboratories indicate that these models may pass 
the FDA clearance process provided they also pass the flammability requirement. As 
expected, the numbers of respirator samples that failed the test increased with increasing test 
velocity. Respirator design, using different numbers of both hydrophilic and hydrophobic 
filter media layers at different packing densities, may influence resistance to blood 
penetration.
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Effect of test velocity on the synthetic blood penetration for 6 N95 filtering facepiece 
respirators (A, B, C, D, E, and F), 3 surgical N95 filters (G, H, and I) and 2 surgical masks (I 
and J). Penetration was tested at 450 cm/sec and 635 cm/sec velocities for all samples of 
different models at both National Institute for Occupational Safety and Health and the third-
party independent laboratories.
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Synthetic blood penetration through different layers of N95 filtering facepiece respirator 
(N95 FFR) models C, A, and D. The outside and inside (a and b, c and d, and e and f, 
respectively) of the outer (1), middle (2), and inner (3) layers of the N95 FFR models. 
Model C represents 1 of the models that passed the penetration test. Model D had only 2 
layers.
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